Shilpa Medicare’s Unit VI in Bengaluru receives Establishment Inspection Report (EIR) with VAI classification from the USFDA for its complex dosage manufacturing facility. The site is already approved by global regulators and supplies oral films to the US and other markets.
Comments
Post a Comment